CA2546057A1 - Method to improve the efficacy of therapeutic radiolabeled drugs - Google Patents

Method to improve the efficacy of therapeutic radiolabeled drugs Download PDF

Info

Publication number
CA2546057A1
CA2546057A1 CA002546057A CA2546057A CA2546057A1 CA 2546057 A1 CA2546057 A1 CA 2546057A1 CA 002546057 A CA002546057 A CA 002546057A CA 2546057 A CA2546057 A CA 2546057A CA 2546057 A1 CA2546057 A1 CA 2546057A1
Authority
CA
Canada
Prior art keywords
drug
ibritumomab tiuxetan
yttrium
moiety
labeled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002546057A
Other languages
English (en)
French (fr)
Inventor
Werner Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering Aktiengesellschaft
Werner Krause
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft, Werner Krause filed Critical Schering Aktiengesellschaft
Publication of CA2546057A1 publication Critical patent/CA2546057A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002546057A 2003-12-11 2004-12-13 Method to improve the efficacy of therapeutic radiolabeled drugs Abandoned CA2546057A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52847303P 2003-12-11 2003-12-11
US60/528,473 2003-12-11
PCT/IB2004/004428 WO2005056058A2 (en) 2003-12-11 2004-12-13 Radiosensitizer conjugate to improve the efficacy of radiolabeled drugs

Publications (1)

Publication Number Publication Date
CA2546057A1 true CA2546057A1 (en) 2005-06-23

Family

ID=34676848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002546057A Abandoned CA2546057A1 (en) 2003-12-11 2004-12-13 Method to improve the efficacy of therapeutic radiolabeled drugs

Country Status (14)

Country Link
EP (1) EP1691838A2 (es)
JP (1) JP2007528874A (es)
KR (1) KR20060118542A (es)
CN (1) CN101031319A (es)
AU (1) AU2004296621A1 (es)
BR (1) BRPI0417517A (es)
CA (1) CA2546057A1 (es)
CR (1) CR8439A (es)
EC (1) ECSP066618A (es)
IL (1) IL175674A0 (es)
MX (1) MXPA06006683A (es)
NO (1) NO20063207L (es)
RU (1) RU2006124510A (es)
WO (1) WO2005056058A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
CN106975078B (zh) * 2017-03-31 2020-11-10 国家纳米科学中心 一种包含多钨酸钆的纳米材料作为增敏剂的用途
WO2024013272A1 (en) * 2022-07-13 2024-01-18 Universite De Montpellier Combined therapy with nanoparticles and radiopharmaceuticals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022404A1 (es) * 1999-01-25 2002-09-04 Photogen Inc Metodo y agentes para la terapia de radiacion mejorada
AU2001249608A1 (en) * 2000-03-28 2001-10-08 Beth Israel Deaconess Medical Center Bladder cancer-specific peptides for diagnosis and therapy
EA007388B1 (ru) * 2001-01-29 2006-10-27 Идек Фармасьютикалз Корпорейшн Модифицированные антитела и способы применения
EP1534336A4 (en) * 2002-08-15 2005-12-14 Human Genome Sciences Inc ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS

Also Published As

Publication number Publication date
AU2004296621A1 (en) 2005-06-23
MXPA06006683A (es) 2006-08-11
CR8439A (es) 2006-12-07
RU2006124510A (ru) 2008-01-20
ECSP066618A (es) 2006-10-25
IL175674A0 (en) 2006-09-05
KR20060118542A (ko) 2006-11-23
NO20063207L (no) 2006-07-10
BRPI0417517A (pt) 2007-03-06
WO2005056058A3 (en) 2006-04-13
JP2007528874A (ja) 2007-10-18
WO2005056058A2 (en) 2005-06-23
EP1691838A2 (en) 2006-08-23
CN101031319A (zh) 2007-09-05

Similar Documents

Publication Publication Date Title
ES2247069T3 (es) Liposomas terapeuticos radioactivos.
EP1245031B1 (en) Method of producing actinium-225 and daughters
JP5468597B2 (ja) 軟組織疾患の放射線治療におけるトリウム−２２７を用いた医薬組成物、複合体及びその調製方法、並びにキット
US6670456B2 (en) Actinium-225 complexes and conjugates for targeted radiotherapy
AU2002306598A1 (en) Actinium-225 complexes and conjugates for targeted radiotherapy
US20060228297A1 (en) Thorium-227 for use in radiotherapy of soft tissue disease
Steffen et al. Biodistribution of 211At labeled HER-2 binding affibody molecules in mice
CA2381123C (en) Actinium-225 complexes and conjugates for radioimmunotherapy
CA2546057A1 (en) Method to improve the efficacy of therapeutic radiolabeled drugs
US20060127308A1 (en) Method to improve the efficacy of therapeutic radiolabeled drugs
JP3794517B2 (ja) 腫瘍診断剤
Pagano et al. Radiopharmaceuticals for bone metastases
JP4339846B2 (ja) 腫瘍治療剤
Soloway et al. 10B+ n,+[nB]+ 7Li (0.87 MeV)+ a (1.52 MeV). tn Table 1.
Norman with Yttrium Macrocycles

Legal Events

Date Code Title Description
FZDE Discontinued